Immunization Back-Up Technician (Af)

Front 1

All organs and systems in the body are subject to anaphylaxis.

Back 1

True

Front 2

What is the appropriate dosage when administering 1:2000 aqueous Intramuscular via EpiPen Junior?

Back 2

0.15mL

Front 3

Stimulation of which division of the autonomic nervous system causes the release of epinephrine?

Back 3

Sympathetic division

Front 4

Epinephrine is referred to as adrenaline and causes ______?

Back 4

vasoconstriction/bronchodilation

Front 5

What effect does epinephrine have on cardiac activity?

Back 5

Epinephrine stimulates the receptor cells of the smooth cardiac muscle causing the heart rate and blood pressure to increase.

Front 6

What is the most dangerous aspect of a vasovagal episode?

Back 6

Injuries obtained from the fall

Front 7

There are two types of syringe tips - plan and locking.

Back 7

True

Front 8

What is the most common type of syringe used for administration of parenteral injections?

Back 8

plastic

Front 9

Syringe selection is based on _____?

Back 9

purpose of the injection, the volume of vaccine to be injected and the need for accuracy in dosage

Front 10

The most accurate size syringe is the _____?

Back 10

1 mL

Front 11

Prepackaged units_________

Back 11

guarantee accuracy, are convenient for normal use, are especially convenient for emergency situations

Front 12

The gauge of a needle is an inverse measurement of the diameter. As the diameter increases, the gauge decreases.

Back 12

True

Front 13

Which of the following should be considered when selecting a needle for administering injections?

Back 13

size of the muscle, thickness of adipose tissue at injection site, volume of material to be administered

Front 14

Because vaccine administered parenterally is almost totally absorbed rather than being partially destroyed by the digestive system, a smaller dosage will achieve the same therapeutic effect.

Back 14

True

Front 15

Only the purpose and characteristics of the vaccine determine the route of administration.

Back 15

False

Front 16

Of the different sites available for an intramuscular injection for an adult, which site has the best blood supply and the most rapid response?

Back 16

Deltoid Muscle

Front 17

What steps can you take to prevent nosocomial infections and associated complications?

Back 17

hand washing, maintain sterility of equipment, cleaning of the injection site

Front 18

When preparing a syringe for vaccine administration you notice the package is partially open. What should you do?

Back 18

get a new syringe

Front 19

The proper procedure for drawing vaccine from a vial is?

Back 19

Remove the protective cap on the vial and clean off the diaphragm with an alcohol swab. Pull back the plunger to aspirate the needed amount of air and insert the needle in the center of the rubber diaphragm. Inject the air and aspirate the vaccine.

Front 20

When reconstituting a multi-dose vaccine you should_________?

Back 20

Label the vial with the date and time mixed

Front 21

What steps should you take before administering a vaccine?

Back 21

Follow the 6 rights of medication administration

Front 22

What is the mot commonly used area for the administration of Intradermal injections?

Back 22

ventral surface of forearms

Front 23

The most common site for subcutaneous injections is the

Back 23

triceps

Front 24

Which intramuscular injection site presents the most risk because of proximity to the large sciatic nerve?

Back 24

Gluteal sites

Front 25

Choose the correct intramuscular injection needle angle when administering an injection into the deltoid muscle

Back 25

90 degrees

Front 26

Vaccines can be given in the gluteal area to pediatric patients

Back 26

False

Front 27

Active immunity ________?

Back 27

is a reaction that stimulates antibody production, appears following exposure to an antigen, is a direct result of an immune response

Front 28

Artificially acquired passive immunity results from the administration of a specific _____?

Back 28

antibody

Front 29

The prescribed dosage and route for anthrax vaccine is ____ with a possible mild ____ reaction.

Back 29

0.5mL IM; local, systemic

Front 30

The recommended booster dose for the Anthrax vaccine is _____

Back 30

Annually if continued immunity is needed

Front 31

What is the routine schedule for Hepatitis-B vaccination?

Back 31

Day-30, day-60, day-180

Front 32

A patient with a history of an anaphylactic reaction after ingestion of eggs should not receive a(n) ______ vaccination before they are skin tested.

Back 32

Influenza

Front 33

The Td booster dose is administered _________

Back 33

every 10 years throughout lifetime

Front 34

What is the dosage requirement for a child for Recombivax (Hepatitis-B) vaccine?

Back 34

0.50mL IM Deltoid muscle (<20 years of age)

Front 35

A 6-month-old healthy child presents for routine immunizations. Child is up to date through 4 months of age. What vaccines are required?

Back 35

DTap, HiB, Prevnar, IPV

Front 36

An 8-week healthy child presents for routine immunization. The child has no immunizations to date. What vaccines are required?

Back 36

Comvax, Prevnar, IPV, DTap

Front 37

Primary immunization series for the Pediarix vaccine is?

Back 37

2, 4, and 6 months

Front 38

Smallpox vaccine (ACAM2000) is administered ____ route.

Back 38

Percutaneous

Front 39

How many jabs does an individual receive if receiving the Smallpox vaccine for the first time?

Back 39

15

Front 40

TB test are administered intradermally on the volor aspect of either forearm. About how far below the bend in the elbow should it be placed?

Back 40

4 inches

Front 41

International health threat assessments are conducted by which governing agency?

Back 41

Defense Intelligence Agency Armed Forces Medical Intelligence Center (AFMIC)

Front 42

AFJI 44-102 outlines immunization guidelines for active duty personnel on alert status

Back 42

True

Front 43

Can waivers for religious reasons be revoked if the mission is compromised?

Back 43

Yes

Front 44

Who has the responsibility for ensuring that military and nonmilitary personnel who are subject to rapid deployment, receive all required immunizations?

Back 44

Do you have allergies to any medications, foods or vaccines?
Are you or a family member immunocompromised/deficient due to medication, treatment, or disease?
Are ou pregnant or have the intention of becoming pregnant in the next three months?

Front 45

When annotating immunization records =, using a signature stamp is authorized.

Back 45

False

Front 46

When transcribing an adult's immunization record, only transcribe immunizations that are _______

Back 46

once in a lifetime, current and in a series

Front 47

IAW WHO Article 80, what document is considered adequate proof of vaccination for armed forces personnel?

Back 47

DD Form 2766C, Vaccine Administration Record

Front 48

At the time of initial immunization of Air Force non-military personnel, a DD form 2766C is established. Which other form can you use to document the immunization?

Back 48

International Certificate of Vaccination or Prophylaxis (ICVP)

Front 49

Anthrax
indicated ages

Back 49

individuals between 18-65

Front 50

Anthrax
Primary Series
Booster

Back 50

consists of 5 intramuscular doses at 0 and 4 weeks and 6, 12 and 18 months
Yearly booster 0.5mL still risk

Front 51

Anthrax
contraindications

Back 51

Severe allergic reaction (e.g. anaphylaxis) after a previous dose of BioThrax

Front 52

Anthrax
Storage/Management

Back 52

2 to 8 degrees C
(36 to 46 degrees F)
Do not use BioThrax after expiration date printed on the label

Front 53

Hepatitis A
Indications

Back 53

19 year and older
All active duty
arrears of high endemicity
persons in high-risk sexual activity

Front 54

Hepatitis A
dosage

Back 54

1.0mL in deltoid

Front 55

Hepatitis A
primary series

Back 55

single dose given followed with a booster dose 6-12 for Havrix
6-18 months later for Vaqta

Front 56

Hepatitis B Vaccine
Indications

Back 56

Infants including those born to HBsAg positive mothers
Those born after 21NOV1991
Adolescents
Health Care Professionals
Morticians/Embalmers
Blood Bank/Plasma workers
Prisoners

Front 57

Hepatitis B Vaccine
Dosage

Back 57

1.0mL IM deltoid muscle (>19 years)

Front 58

Hepatitis B Vaccine
Primary Series

Back 58

Three (3) doses regimen.
First dose at elected date, second dose one (1) month later, third dose six (6) months after the first

Front 59

Hepatitis B Vaccine
Contraindications

Back 59

Hypersensitivity to yeast
Any component of the vaccine

Front 60

Human Papillomavirus (GARDASIL)
indications

Back 60

females 9-26 years of age
prevention of HPV types 6,11,16 &18

Front 61

Human Papillomavirus
(GARDASIL)
dosage

Back 61

0.5mL IM

Front 62

Human Papillomavirus
(GARDASIL)
primary series

Back 62

First dose: at elected date
Second dose: 2 months after the first
Third dose: 6 months after the first

Front 63

Human Papillomavirus
(GARDASIL)
contraindication

Back 63

Hypersensitivity to the active substances or to any of the excipients of the vaccine

Front 64

Influenza (Flu) injectable
indications

Back 64

All active duty
Healthcare workers
persons age less than or equal to 65
Women in the second and third trimester of pregnancy

Front 65

Influenza (Flu) Injectable
dosage

Back 65

0.5mL IM

Front 66

Influenza (Flu) injectable
Primary Series

Back 66

Annually

Front 67

Influenza (Flu) Injectable
contraindications

Back 67

hypersensitivity (allergy) anaphylactic reactions to eggs or egg products
Sensitive to Thimerosal

Front 68

Influenza (Flu) Intranasal
indications

Back 68

All active duty
Healthcare workers
persons 2-49 years
healthy children and adults

Front 69

Influenza (Flu) Intranasal
dosage

Back 69

0.20mL

Front 70

Influenza (Flu) Intranasal
primary series

Back 70

Annually

Front 71

Influenza (Flu) Intranasal
contraindications

Back 71

No administration parenterally
Hypersensitivity to eggs or egg products
children/adolescents 2-17 years
history of Guillain-Barre syndrome

Front 72

Japanese Encephalitis Vaccine
indications

Back 72

month or longer in endemic areas during transmission season
lab workers exposed to virus
specific guidance for AD by MAJCOM

Front 73

Japanese Encephalitis Vaccine
dosage

Back 73

1.0mL patient 3 yrs and older SQ
0.50mL 35 months to 1 yr SQ

Front 74

Japanese Encephalitis Vaccine
primary series

Back 74

three (3) doses given 0, 7 and 30 days
third dose at least 10 days before travel

Front 75

Japanese Encephalitis Vaccine
contraindication

Back 75

allergic reaction to prior dose or vaccine components
persons with multiple allergies; hx of urticria or angiodema
pregnancy

Front 76

Measles, Mumps, Rubella (M-M-RII)
indications

Back 76

12 months or older
adults born in 1957 or later
college students
healthcare personnel
women of childbearing age
international travel

Front 77

Measles, Mumps, Rubella (M-M-RII)
dosage

Back 77

0.5mL SQ

Front 78

Measles, Mumps, Rubella (M-M-RII)
primary series

Back 78

one (1) dose for adults

Front 79

Measles, Mumps, Rubella (M-M-RII)
second dose

Back 79

If recommended, minimum of 4 weeks between the 1st and 2nd shot

Front 80

Measles, Mumps, Rubella (m-M-RII)
contraindications

Back 80

Hypersensitivity to any component; include gelatin
Pregnancy
Febrile infection
Anaphylactic/anaphylacoid to neomycin
Pt receiving immunosuppressive therapy
pt w/ HIV, disease affecting the bone marrow or lymphatic system

Front 81

Meningococcal Polysaccharide Vaccine Group A,C,Y and W-135 Combined (Menomune-A/C/Y/W-135)
dosage

Back 81

0.5mL SQ

Front 82

Meningococcal Polysaccharide Vaccine Group A,C,Y and W-135 Combined (Menomune-A/C/Y/W-135)
Primary Series

Back 82

Single dose

Front 83

Meningococcal Polysaccharide Vaccine Group A,C,Y and W-135 Combined (Menomune-A/C/Y/W-135)
indications

Back 83

deficiencies in late Complement components
functional/actual asplenia
lab
travelers/residents hyperendemic areas

Front 84

Meningococcal Polysaccharide Vaccine Group A,C,Y and W-135 Combined (Menomune-A/C/Y/W-135)
contraindications

Back 84

hx or adverse reaction to Thimerosal
defer immunization during the course of any acute illness

Front 85

Meningococcal (Group A,C,Y and W-135) Polysaccharide Diptheria Toxoid Conjugate Vaccine Menactra
indications

Back 85

licensed for ages 2-55 years
travelers to hyperendmic areas

Front 86

Meningococcal (Group A,C,Y and W-135) Polysaccharide Diptheria Toxoid Conjugate Vaccine Menactra
dosage

Back 86

0.5mL IM

Front 87

Meningococcal (Group A,C,Y and W-135) Polysaccharide Diptheria Toxoid Conjugate Vaccine Menactra
primary series

Back 87

single dose

Front 88

Meningococcal (Group A,C,Y and W-135) Polysaccharide Diptheria Toxoid Conjugate Vaccine Menactra
contraindications

Back 88

hx of adverse reaction to Thimerosal
Defer immunization during course of any acute illness

Front 89

Inactivated Polio Vaccine
(IPV, e-IPV, ep-IPV)
indications

Back 89

travelers to endemic regions
Healthcare workers exposed
Lab workers exposed
All active duty required to have one (1) dose

Front 90

Inactivated Polio Vaccine
(IPV, e-IPV, ep-IPV)
dosage

Back 90

0.5mL SQ/IM (IPV)

Front 91

Inactivated Polio Vaccine
(IPV, e-IPV, ep-IPV)
primary dose

Back 91

unvaccinated adults:
two doses 4-8 weeks apart
followed by third 6-12 months after 2nd dose
day-0, day-30, 6-12 months

Front 92

Inactivated Polio Vaccine
(IPV, e-IPV, ep-IPV)
contraindications

Back 92

hx of hypersensitivity to vaccine; 2-phenoxyethanol, formaldehyde, neomycin, streptomycin and polymyxin
Person w/ acute febrile illiness

Front 93

Pneumococcal Vaccine (PPV 23)

Back 93

pts 2 yr and older; routine vaccination for persons 50 years or older

Front 94

Pneumococcal Vaccine (PPV 23) dosage

Back 94

0.50 mL SQ/IM
one dose

Front 95

Rabies Vaccine
primary series - pre-exposure

Back 95

three (3) doses
day -0, day - 7 and day-21 to 28

Front 96

Rabies Vaccine
primary series - post exposure

Back 96

give rabies immune globulin asap, followed by five (5) doses day-0, day-3, day-7, day-14 and day-28

Front 97

Rabies Vaccine
dosage

Back 97

1.mL IM deltoid

Front 98

Shingles {Zostavax}, Live
primary series

Back 98

single dose, 0.65mL SQ

Front 99

Shingles {Zostavax}, Live
contraindications

Back 99

hx of allergic reaction to gelatin, neomycin, or compnent of vaccine
hx of immunodeficiency
Immunosuppressive therapy
Active untreated TB
Pregnant

Front 100

Smallpox (AMSAM2000), Live
primary

Back 100

administred percutaneous route (scarification) using 15 jabs

Front 101

Smallpox (AMSA2000), Live
storage

Back 101

freezer temperature of -15 to -25 degrees C

Front 102

Tetanus/Diphtheria (Td)
indications

Back 102

Pt 7 years and older
New recruites

Front 103

Tetanus/Diphtheria (Td)
dosage

Back 103

0.5mL IM

Front 104

Tetanus/Diphtheria (Td)
primary Series

Back 104

Two (2) doses given at an interval of 4 to 8 weeks, following a third reinforcing dose 6 to 12 months after the second dose
Booster at 10-year intervals

Front 105

Tdap (ADACEL)

Back 105

active booster immunization of tetanus, diphtheria and pertussis, 11-64 years

Front 106

Tdap (ADACEL)
dosage

Back 106

single dose 0.5mL IM

Front 107

Tdap - Boostrix
dosage

Back 107

05.50 mL, IM

Front 108

Tdap - Boostrix

Back 108

10-64 yr as a booster to the promary series

Front 109

Twinrix (Hepatitis A inactivated & Hepatitis B (Rocombiant) Vaccine
indications

Back 109

chronic liver disease
risk through work
Healthcare workers
daycare or correctional employees
men having sex with men
military recruits

Front 110

Twinrix (hepatitis A inactivated & Hepatitis B (Recombiant)
dosage

Back 110

1.0mL IM, primary for adults three (3) doses, day-0, 1 month and 6-month mark

Front 111

Typhoid Vaccine (Oral, Ty21a), Live
indications

Back 111

All active duty on mobiility status

Front 112

Typhoid Vaccine (Oral, Ty21a), Live
dosage

Back 112

4 capsules orally, one (1) taken every other day

Front 113

Typhoid Vaccin (Typhim Vi), parenteral
dosage

Back 113

0.5mL IM

Front 114

Varicella Virus Vaccine (Chickenpox) (Varivax), Live
indications

Back 114

> or equal to 12 months of age
high-risk occupational groups

Front 115

Varicella Virus Vaccine (Chickenpox) (Varivax), Live
dosage

Back 115

0.5mL SQ
two (2) doses four to eight weeks apart

Front 116

Yellow Fever, Live
indications

Back 116

persons >or equal to 9 months of age traveling/living in areas of South America and Africa
Lab personnel who may be exposed

Front 117

Yellow Fever, Live

Back 117

single dose, 0.5ml SQ, booster every 10 yrs

Front 118

Yellow Fever, Live
contraindications

Back 118

Allergic to eggs
Mercury sensitivity
antibiotic indused allegic reaction
hypersensitvity to vaccine components

Front 119

Adult Immunization Schedule

Back 119

Td/Tdap - 1 time dose, then booster every 10 yr (19-65)
HPV - 3 doses, females 19-26
Varicella - 2 doses 19 and up
Zoster - 1 dose, 60 yr and up
MMR - 1 or 2 doses, 19-49; 1 dose 50 and up
Influenza - 1 dose annually 19 and up
Pneumococcal - 1 or 2 dose, 19-64; 1 dose 65 and older
Hepatitis A - 2 doses, 19 and older
Hepititis B - 3 doses 19 and older
Meningococcal - 1 or more doses, 19 and older

Front 120

Comvax
(Hib and Hep B combination)
schedule

Back 120

administer at 2, 4 and 12-15 months of age

Front 121

Comvax
(Hib and Hep B combination)
dosage

Back 121

0.50mL; IM

Front 122

Comvax
(Hib and Hep B combination)
contraindications

Back 122

Hypersensitvity to yeast
any components

Front 123

DT
schedule

Back 123

2 months
4 months
6 months
15-18 months
4 - 6 yrs of age

Front 124

DT
dosage

Back 124

0.50mL; IM

Front 125

DT
contraindications

Back 125

hypersensitivity to component
hypersensitivity to Thimerosal

Front 126

DTap/DTP
schedule

Back 126

2, 4, 6, 15-18 months
4-6 years of age
Doses 2&3 can be given 4 weeks after previous dose while dose 4 should be given at least 6 months after dose3. If dose 4 is givven before child's 4th birthday give dose 5 at lease 6 months later. If given after the 4th birthday dose 5 is not necessary

Front 127

DTap/DTP
dosage

Back 127

05.50mL; IM

Front 128

DTap/DTP
contraindications

Back 128

hypersensitivityto components
hypersensitivity to Thimerosal
Gelatin

Front 129

DTap-IPV (Kinrix)
schedule

Back 129

5th dose in DTap series
4th dose in IPV series in children 4-6 years of age

Front 130

DTap-IPV (Kinrix)
dosage

Back 130

0.5mL, IM
preferred deltoid upper arm

Front 131

DTap-IPV (Kinrix)
contraindications

Back 131

hypersensitivity
encephalopathy
progressive neurologic disorder

Front 132

DTap-IPV/Hib (Pentacel)
schedule

Back 132

2, 4, 6, 15 - 18 months

Front 133

DTap-IPV/Hib (pentacel)
dosage

Back 133

0.5mL, IM

Front 134

DTap-IPV/Hib (Pentacel)
contraindications

Back 134

hypersensitivity
encephalopathy
progressive neurologic disorder

Front 135

Haemophilus Influenza type B (HIB)
HibTITER (Wyeth)
PedvaxHIB (merck)
ActHIB (Sanofi-Pasteur)
contraindications

Back 135

prior reaction
hx of hypersensitivitiy to components, Thimersol

Front 136

Hepatitis A
schedule

Back 136

1- 18 yrs old
two doses 6 - 12 months apart

Front 137

Hepatitis A
dosage

Back 137

0.50mL; IM

Front 138

Hepatitis A
contraindications

Back 138

anaphylaxis to components

Front 139

Hepatitis B (HBV)
schedule

Back 139

"A" - birth, 2 months, 1-4 months oldand 6-18 months old
"B" - day 0, day 30 and day 180 (for older children)

Front 140

Hepatitis B (HBV)
dosage

Back 140

0.50mL; IM

Front 141

Hepatitis B (HBV)
contrainidications

Back 141

anaphylaxis to previous dose, vaccine component, yeast and Thimerosal

Front 142

Inactivated Polio (IPV)
schedule

Back 142

2, 4, 6-18 months and 4-6 years of age

Front 143

Inactivated Polio (IPV)
dosage

Back 143

0.50mL; SQ or IM

Front 144

Inactivated Polio (IPV)
contraindications

Back 144

anaphylaxis to components or previous dose

Front 145

Comvax
(Hib and Hep B combination)
schedule

Back 145

administer at 2, 4 and 12-15 months of age

Front 146

Comvax
(Hib and Hep B combination)
dosage

Back 146

0.50mL; IM

Front 147

Comvax
(Hib and Hep B combination)
contraindications

Back 147

Hypersensitvity to yeast
any components

Front 148

DT
schedule

Back 148

2 months
4 months
6 months
15-18 months
4 - 6 yrs of age

Front 149

DT
dosage

Back 149

0.50mL; IM

Front 150

Influenza (Flu) injectable
schedule

Back 150

age 9 and older: one dose annually
age 8 or younger previously unvaccinated: two doses 1 month apart

Front 151

Influenza (Flu) injectable
dosage

Back 151

3 and older 0.50mL IM
6 - 35 months 0.25mL IM

Front 152

Influenza (Flu) injectable
contraindications

Back 152

eggs and Thimersol or reaction to previous dose

Front 153

Influenza (Flu) intranasal

Back 153

2-49 years
0.20mL

Front 154

Measles, Mumps, Rubella
(M-M-RII), Live
schedule

Back 154

two doses 12-15 months and 4-6 years old

Front 155

Measles, Mumps, Rubella
(M-M-RII), Live
dosage

Back 155

0.50mL; SC

Front 156

Measles, Mumps, Rubella
(M-M-RII), Live
contraindications

Back 156

anaphy;axis to components, eggs or neomycin

Front 157

Measles, Mumps, Rubella
and Varicella (MMRV-ProQuad), Live
schedule

Back 157

routine - 12-18 months
individuals 12 months - 12 years should recieve a single 0.5mL dose of ProQuad SQ

Front 158

Measles, Mumps, Rubella
and Varicella (MMRV-ProQuad), Live
contraindications

Back 158

reaction to neomycin
hypersensitivity to gelatin
immunosuppresive therapy
untreated TB

Front 159

PEDIARIX (diphtheria, tetanus toxoid and pertusis absorbed, Hepatitis B (Recombiant) and Inactivated Poliovirus Vaccine Combined)
schedule

Back 159

3 doses - 2 months, 4 months and 6 months of age

Front 160

PEDIARIX (diphtheria, tetanus toxoid and pertusis absorbed, Hepatitis B (Recombiant) and Inactivated Poliovirus Vaccine Combined)
contraindications

Back 160

sensitivity to components
yeast
neomycin
polymyxin
previous dose

Front 161

PEDIARIX (diphtheria, tetanus toxoid and pertusis absorbed, Hepatitis B (Recombiant) and Inactivated Poliovirus Vaccine Combined)
dosage

Back 161

0.50mL; IM

Front 162

Pneumococcal Conjugate Prevnar (PCV7)
schedule

Back 162

2, 4, 6, & 12- 15 months of age
older children at risk: 7-11 months old two doses two months apart, another dose 15-18 months. 12-23 months two doses two months apart and 24months - 9 years one dose

Front 163

Pneumococcal Conjugate Prevnar (PCV7)
dosage

Back 163

0.50mL; IM

Front 164

Pneumococcal Conjugate Prevnar (PCV7)
contraindications

Back 164

anaphylaxisis to components, diphtheria toxioid

Front 165

ROTARIX, Live
schedule

Back 165

administer first dose to infants beginning 6 weeks of age
second dose after at leaset 4 weeks and prior to 24 weeks of age

Front 166

ROTARIX, Live
dosage

Back 166

1-mL orally

Front 167

ROTARIX, Live
contraindication

Back 167

Hx of uncorrected congential malformation of the GI tract

Front 168

RotaTeq [Rotavirus Vaccine, Live, Oral, Pentavalent]
schedule

Back 168

3 ready to use, start at 6 to 14 weeks of age, with subsequent doses administered at 4- to 10- week intervals

Front 169

RotaTeq [Rotavirus Vaccine, Live, Oral, Pentavalent]
dosage

Back 169

2 mL Orally

Front 170

RotaTeq [Rotavirus Vaccine, Live, Oral, Pentavalent]
contraindications

Back 170

Hx of hypersensitivity to components
sensitivity to first dose

Front 171

TriHIBit (DTap and HIB)
schedule

Back 171

12-18 months old ONLY

Front 172

TriHIBit (DTap and HIB)
dosage

Back 172

0.50ml; IM

Front 173

TriHIBit (DTap and HIB)
contraindications

Back 173

Hx of pertussus or components containing pertussis in vaccine
Thimerosal
Encephalopathy

Front 174

Varicella, Live
schedule

Back 174

Children: routine 12-18 months and 4-6 yrs of age, if second dose administered a minimum of 3 months later.
Adolescents: 13 yrs and older at elected date and a second 4-6 weeks later

Front 175

Varicella, Live
dosage

Back 175

0.5mL; SQ

Front 176

Varicella, Live
contrindications

Back 176

anaphylaxsis to components
neomycin
gelatin
MSG

Front 177

Purified Protein Derivative (PPD) 5TU Strength; delayed skin test

Back 177

read 48 to 72 hours after injection
0.1mL of 5TU strength intradermal